Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Prostate Cancer
PROSTATE ADVISOR
FEATURED CONTENT
-
-
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services. -
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol. -
Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
At 23 years of follow-up, the cumulative incidence of death was higher among patients in the watchful waiting group compared with those in the radical prostatectomy group. -
Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
“People have shown that the variant-identification quality of WGS is superior to WES,” said Dr Gerstein.
Current Research Into Pain Assessment
Immunotherapy for Prostate Cancer
Targeted Agents
Targeted Agents (cont.)
Radium-223
Chemotherapy
Immunotherapy
Treatment Sequencing
Androgen Deprivation Therapy
Duration of ADT
Docetaxel in Combination With ADT
HSD3B1 Allele Inheritance Linked With ADT Resistance
ADT and Radiation
Predictions for the Future
PROSTATE CANCER NEWS
Investigational Antiandrogen Drug Delays Metastasis in CRPC
Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
Newer mCRPC Drugs Led to Longer Survival in African American Patients
Metastatic Prostate Cancer Responds to Novel Radiation Therapy
PCa Genomic Test May Predict Outcomes More Accurately in African-American Men
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
